NASDAQ:QTNTQuotient Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Quotient Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.78 -0.30 (-4.24 %) (As of 08/7/2020 02:21 PM ET) Add Compare Share Today's Range$6.78Now: $6.78▼$6.9850-Day Range$6.97MA: $7.82▼$8.4752-Week Range$2.39Now: $6.78▼$11.10Volume16,158 shsAverage Volume670,137 shsMarket Capitalization$546.54 millionP/E RatioN/ADividend YieldN/ABeta2.61 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Quotient. Previous Next 2.4 Community Rank Outperform VotesQuotient has received 290 “outperform” votes. (Add your “outperform” vote.)Underperform VotesQuotient has received 307 “underperform” votes. (Add your “underperform” vote.)Community SentimentQuotient has received 51.42% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote “Outperform” if you believe QTNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldQuotient does not currently pay a dividend.Dividend GrowthQuotient does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quotient insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,311.00 in company stock.Percentage Held by InsidersOnly 12.30% of the stock of Quotient is held by insiders.Percentage Held by Institutions73.76% of the stock of Quotient is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Quotient are expected to grow in the coming year, from ($1.27) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quotient is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quotient is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.81 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTNT Previous Symbol CUSIPN/A CIK1596946 Webwww.quotientbd.com Phone011-41-22-716-9800Debt Debt-to-Equity Ratio9.74 Current Ratio4.83 Quick Ratio4.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$32.66 million Price / Sales16.73 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-96.86Profitability EPS (Most Recent Fiscal Year)($1.44) Net Income$-102,770,000.00 Net Margins-313.16% Return on EquityN/A Return on Assets-48.19%Miscellaneous EmployeesN/A Outstanding Shares80,610,000Market Cap$546.54 million Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $6.78 -0.30 (-4.24 %) (As of 08/7/2020 02:21 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive QTNT News and Ratings via Email Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter. Quotient (NASDAQ:QTNT) Frequently Asked Questions How has Quotient's stock been impacted by COVID-19 (Coronavirus)? Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTNT shares have increased by 47.0% and is now trading at $6.82. View which stocks have been most impacted by Coronavirus. When is Quotient's next earnings date? Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Quotient. How were Quotient's earnings last quarter? Quotient Ltd (NASDAQ:QTNT) posted its earnings results on Monday, August, 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. View Quotient's earnings history. What guidance has Quotient issued on next quarter's earnings? Quotient updated its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million. Has Quotient been receiving favorable news coverage? Media stories about QTNT stock have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quotient earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Quotient. Who are some of Quotient's key competitors? Some companies that are related to Quotient include Intellia Therapeutics (NTLA), Heska (HSKA), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO) and Achieve Life Sciences (ACHV). View all competitors. What other stocks do shareholders of Quotient own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Verastem (VSTM), Gilead Sciences (GILD), Novavax (NVAX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL) and Clovis Oncology (CLVS). Who are Quotient's key executives? Quotient's management team includes the following people: Mr. Franz Walt, CEO & Director (Age 60)Mr. Jeremy Stackawitz, Pres (Age 44)Mr. Edward Farrell, Pres (Age 49)Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)Mr. John Allan, Corp. Sr. VP & CTO What is Quotient's stock symbol? Quotient trades on the NASDAQ under the ticker symbol "QTNT." Who are Quotient's major shareholders? Quotient's stock is owned by a variety of institutional and retail investors. Top institutional investors include Swiss National Bank (0.17%), Roubaix Capital LLC (0.14%), M&T Bank Corp (0.12%), DAVENPORT & Co LLC (0.12%), New York State Common Retirement Fund (0.07%) and SG Americas Securities LLC (0.04%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd. View institutional ownership trends for Quotient. Which institutional investors are selling Quotient stock? QTNT stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, Swiss National Bank, and Arizona State Retirement System. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz, and Roland Boyd. View insider buying and selling activity for Quotient. Which institutional investors are buying Quotient stock? QTNT stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, New York State Common Retirement Fund, SG Americas Securities LLC, M&T Bank Corp, UBS Group AG, and Ameritas Investment Partners Inc.. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von. View insider buying and selling activity for Quotient. How do I buy shares of Quotient? Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Quotient's stock price today? One share of QTNT stock can currently be purchased for approximately $6.82. How big of a company is Quotient? Quotient has a market capitalization of $549.76 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. What is Quotient's official website? The official website for Quotient is www.quotientbd.com. How can I contact Quotient? Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800. This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
